Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4896 results
Oxford and Menarini begins first-in-human trial of leukemia drug OBT357
By PBR Staff Writer
Oxford BioTherapeutics and Menarini Group have started the first-in-human clinical trial of OBT357 (MEN1112), a new improved antibody to treat acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
AstraZeneca's Duaklir Genuair gets marketing approval in Europe for COPD
By PBR Staff Writer
AstraZeneca has received marketing authorisation from the European Commission (EC) for its Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12mcg) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Drug Research > Drug Discovery & Development > News
ZS Pharma reports results from Phase III study of ZS-9 in patients with hyperkalemia
ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM).
Drug Research > Drug Discovery & Development > News
CHMP grants positive opinions of AbbVie's VIEKIRAX + EXVIERA to treat chronic hepatitis C
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) + EXVIERA (dasabuvir) with or without ribavirin (RBV) for patients with genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infection.
Drug Research > Drug Discovery & Development > News
Heptares Orphan disease program awarded grant from UK Biomedical catalyst
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce that it has been awarded a £1.5 million grant from the UK Biomedical Catalyst, a funding programme jointly operated by the UK Medical Research Council (MRC) and Innovate UK.
Drug Research > Drug Discovery & Development > News
Alpex Services
Alpex Pharma is a drug delivery business focused on the development and commercial manufacature of effervescent and propriety rapidly dissolving (fast melt) pharmaceutical and nutraceutical products.
Drug Research > Drug Discovery & Development > Products
Cynapsus reports positive top-line results from CTH-105 phase II trial of APL-130277 to treat Parkinson's Disease
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson’s disease, announced positive top-line results from its CTH-105 Phase II clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
ULTImate YChemH
Find out more about your small molecule effects thanks to our drug discovery service. ULTImate Yeast Chemical Hybrid (YChemH) is a compound profiling technique adapted from our ULTImate Y2H™ technology to identify the protein partners of a given bioactive small molecule.
Drug Research > Drug Discovery & Development > Products
Teva introduces liquid formulation of Treanda injection in US
By PBR Staff Writer
Teva Pharmaceutical Industries has launched a liquid formulation of Treanda (bendamustine HCI) Injection in the US indicated to treat patients with chronic lymphocytic leukemia (CLL).
Drug Research > Drug Discovery & Development > News
Edge Therapeutics enters research collaboration with leading academic medical center
Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming the treatment of acute, life-threatening neurological conditions, announced a multi-year research and discovery collaboration with St. Michael’s Hospital, which is affiliated with the University of Toronto.
Drug Research > Drug Discovery & Development > News
FDA allows Fibrocell's IND application for new Wounded Warrior Amputees to prevent stump skin diseases
Fibrocell Science, an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the US Food and Drug Administration is allowing the company's investigational new drug (IND) application to proceed for developing a new treatment for amputee stump skin to prevent skin diseases that lead to prosthesis abandonment.
Drug Research > Drug Discovery & Development > News
Genticel closes patient enrolment in Phase II ProCervix trial
By PBR Staff Writer
French biotechnology firm Genticel has completed patient enrollment in the Phase II trial (RHEIA-VAC) of its lead therapeutic vaccine candidate, ProCervix , to treat human papillomavirus (HPV).
Drug Research > Drug Discovery & Development > News
Alnylam reports positive initial phase II data with Revusiran to treat TTR Cardiac Amyloidosis
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Drug Research > Drug Discovery & Development > News
AstraZeneca begins development programme for BRILINTA reversal agent
AstraZeneca has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA) in rare emergency situations such as urgent surgery, or in the event of major bleeding.
Drug Research > Drug Discovery & Development > News
Galmed doses first patient in its Phase IIa trial of aramchol to treat cholesterol gallstones
By PBR Staff Writer
Israel-based Galmed Pharmaceuticals has dosed first patient in its Phase IIa clinical trial of its drug candidate, aramchol, to treat newly formed cholesterol gallstones following bariatric surgery.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

Hybrigenics Services - Protein Interactions Expert
Who else knows your protein better than you? Who else knows proteins interactions better than us?... Drug Research > Drug Discovery & Development > Suppliers
FeF Chemicals - Insulin Human and Benzalkonium Chloride Products
FeF Chemicals is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.... Drug Research > Drug Discovery & Development > Suppliers
Polipharma Industries - Pharmaceutical Product Manufacturer
Polipharma Industries is a GMP-certified drug manufacturer established in 2003, whose core business is the manufacturing of pharmaceutical products. We provide activities and services such as: research & development, out-licensing, contract manufacturing, contract development, batch release, analytical services and clinical trials.... Drug Research > Drug Discovery & Development > Suppliers
Alpex Pharma - High Quality Formulation Development & Manufacturing Company
Alpex Pharma is a pharmaceutical company active in Research & Development and Production of ODT (Orally Dispersible Tablet) called also "fast melt" and effervescent tablets. Alpex Pharma has developed a unique proprietary covering ODT technology.... Drug Research > Drug Discovery & Development > Suppliers
NNIT - The Full Service IT Consultancy Dedicated to Life Sciences
NNIT specialises in using IT to optimise the complex processes inherent in the life sciences industry. We are an international consultancy in the development, implementation, validation and operation of IT for the life sciences industry. ... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

Technical Training By Natoli Engineering Company
Current training offering: Basics of tablet manufacturing and troubleshooting December 2-4, 2014. A two-day course on tablet manufacturing and troubleshooting for operators across the tablet compression industry.... Drug Research > Drug Discovery & Development > White Papers Prevention and Repair of J-Hook By Natoli Engineering Company
J-hooks are the distinctive wear patterns on punch tips that are a cause of such tablet defects as capping, lamination and poor friability. If detected early, J-hooks can be easily and quickly repaired, thereby eliminating the need to purchase replacement tools.... Drug Research > Drug Discovery & Development > White Papers Why You Should be Using Ultrasonic Cleaning By Natoli Engineering Company
Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling.... Drug Research > Drug Discovery & Development > White Papers Choose the Right Tooling By Natoli Engineering Company
Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.... Drug Research > Drug Discovery & Development > White Papers Eight Ways to Reduce Manufacturing Costs By Natoli Engineering Company
It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to help our customers address these challenges, we put together this list of eight ways to reduce tablet manufacturing costs.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4896 results